Proactive Research analyst Emma Ulker gives her take on the recent trading update from MaxCyte ().
The firm signed five of eight clinical/commercial deals for its proprietary cell engineering Flow Electroporation technology in FY19.
Ulker says the increasing momentum in deal flow echoes the ‘explosive growth’ in the cell and gene therapy sector.
She adds that MaxCyte is in an ‘exceptional position’ to continue to benefit from the growth of the industry given the versatility of its cell engineering platform.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is…
In exchange for publishing services rendered by the Company on behalf of MaxCyte Inc named herein, including the promotion by the Company of MaxCyte Inc in any Content on the Site, the Company receives from said…